Höner Zu Siederdissen Christoph, Maasoumy Benjamin, Cornberg Markus
Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625 Hannover, Germany.
Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625 Hannover, Germany; German Center for Infection Research (DZIF), Partner Site Hannover-Braunschweig, Germany.
Best Pract Res Clin Gastroenterol. 2017 Jun;31(3):281-289. doi: 10.1016/j.bpg.2017.04.009. Epub 2017 May 4.
Challenges in the management of chronic hepatitis B virus (HBV) infection involve the prediction of the natural course to identify patients who require antiviral therapy and the prediction of functional cure as ultimate goal of antiviral therapy. HBV DNA as marker for viral replication is important but not sufficient for an adequate management of patients with chronic HBV infection. Data on the quantification of additional HBV marker such as hepatitis B surface antigen (HBsAg), hepatitis B core-related antigen (HBcrAg) and hepatitis B virus RNA (HBV RNA) have accumulated in recent years. Here we review the current evidence how to use these markers and discuss open issues that require additional research.
慢性乙型肝炎病毒(HBV)感染的管理面临诸多挑战,包括预测疾病自然进程以确定需要抗病毒治疗的患者,以及预测作为抗病毒治疗最终目标的功能性治愈。HBV DNA作为病毒复制的标志物很重要,但对于慢性HBV感染患者的充分管理而言并不足够。近年来,关于其他HBV标志物(如乙型肝炎表面抗原(HBsAg)、乙型肝炎核心相关抗原(HBcrAg)和乙型肝炎病毒RNA(HBV RNA))定量的数据不断积累。在此,我们回顾了如何使用这些标志物的现有证据,并讨论了需要进一步研究的开放性问题。